top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.
Advances in the Treatment of Renal Cell Carcinoma
Advances in the Treatment of Renal Cell Carcinoma
Autore Reynolds Paul
Pubbl/distr/stampa Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022
Descrizione fisica 1 electronic resource (221 p.)
Soggetto topico Medicine
Soggetto non controllato renal cell carcinoma
autophagy
hydroxychloroquine
chloroquine
ROC-325
cysteine cathepsins
cysteine cathepsin inhibitors
lysosome
renal cancer
metastatic renal cell carcinoma
immune-based combination therapies
network meta-analysis
PD-L1
predictive
biomarker
treatment
TKIs
mRCC
biomarkers
soluble factors
immunotherapy
renal cell carcinoma (RCC)
sunitib resistance
artesunate (ART)
Traditional Chinese Medicine (TCM)
growth inhibition
ferroptosis
reactive oxygen species (ROS)
clear cell renal cell carcinoma
ccRCC
RCC
kidney cancer
evolution
evolutionary trajectory
metastatic
second line therapy
renal cell cancer
immune checkpoint inhibitors
tyrosine kinase inhibitors
individualization
genomic signature
transcriptomic analysis
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910557615503321
Reynolds Paul  
Basel, : MDPI - Multidisciplinary Digital Publishing Institute, 2022
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Renal Cell Carcinoma
Renal Cell Carcinoma
Autore López José I
Pubbl/distr/stampa MDPI - Multidisciplinary Digital Publishing Institute, 2020
Descrizione fisica 1 electronic resource (500 p.)
Soggetto topico Renal cell carcinoma
Kidneys - Cancer
Soggetto non controllato N-glycomapping
SMAD proteins
patient survival
pro-IL-1?
survival prediction
inflammation markers
tumor migration
prognostic factors
practical approach
circular RNAs in a clinico-genomic predictive model
glycomarkers
review
nephrectomy
uric acid
VEGF inhibitors
metabolic reprogramming
collecting duct carcinoma
curcumin
metabolome profiling
identification of circular RNAs
IL-2
experimental validation of circular RNA
Raf/MEK/ERK
HOT
PI3K/Akt/mTOR
pentose phosphate pathway
kidney cancer
LOT
mutation
RCC
polybromo-1
pale cell
MMP-9
gene expression
recurrence free survival
chromosomal loss
IL-1?
chronic kidney disease
glutathione transferase omega 2
label-free
glutathione transferase omega 1
emerging entity
copy number alteration
FOXO3
predictive role
tumor slice culture
tyrosine kinase inhibitors
PPP
ESC
CDKN1A expression
metastasis
PD-L1
diagnostic and prognostic markers
EVI1
copy number loss
RNA sequencing
NK cells
glutathione metabolism
clear cell renal cell carcinoma
renal cell cancer
proliferation
eosinophilic variant
Xp11 translocation renal cell carcinoma
prognosis
invasion
immune infiltration
IL4R?
FISH
11) translocation renal cell carcinoma
tumor microenvironment
metabolome
hyperosmolality
toxicity
ALK
drug sensitivity
t(6
copy number analysis
urine
genetic association
polymorphism
solute carrier proteins
kidney
metastatic ccRCC
molecular genetic features
recurrence-free survival
chromophobe renal cell carcinoma
unclassified renal tumor
overall survival
mTOR inhibitors
mTOR
JAK2
von Hippel-Lindau
miR-155-5p
glycoproteomics
PBRM1
miR-133b
survival
TFE3
TFEB
oncocytic renal tumor
immune checkpoint inhibitors
biomarker
MMP10
TCGA
ghrelin
EMT like
checkpoint inhibitors
MiT family translocation renal cell carcinoma
gene signature
sarcomatoid
transforming growth factor beta
clear cell Renal Cell Carcinoma
tumor adhesion
renal cancer
unclassified renal cell carcinoma
Papillary renal cell carcinoma (pRCC)
miR-146a-5p
renal cell
everolimus
integrins
cytoreductive nephrectomy
immunotherapy
predictive factors
immunohistochemistry
MTA2
IL13R?1
targeted therapy
intratumour heterogeneity
aurora A
TCA cycle
AMP-activated protein kinases
cancer-specific survival
programmed death-ligand 1
efficacy
renal cell carcinoma
anaplastic lymphoma kinase rearrangement
TFEB-amplified renal cell carcinoma
statins
cancer immunotherapy
microRNA
new entity
proteome profiling
ISBN 3-03928-639-0
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910404087003321
López José I  
MDPI - Multidisciplinary Digital Publishing Institute, 2020
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Urologic Cancers
Urologic Cancers
Autore Barber Neil
Pubbl/distr/stampa Brisbane, Australia, : Exon Publications, 2022
Soggetto topico MJCL
Soggetto non controllato urologic cancers
prostate cancer
kidney cancer
testicular cancer
bladder cancer
penile cancer
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910617309003321
Barber Neil  
Brisbane, Australia, : Exon Publications, 2022
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Wait Time [[electronic resource] ] : A Memoir of Cancer / / Kenneth Sherman
Wait Time [[electronic resource] ] : A Memoir of Cancer / / Kenneth Sherman
Autore Sherman Kenneth <1950-, >
Pubbl/distr/stampa Waterloo, Ontario : , : Wilfrid Laurier University Press, , [2016]
Descrizione fisica 1 online resource (153 pages)
Disciplina 616.99461
Collana Life writing
Soggetto topico Poets, Canadian (English) - 20th century
Cancer - Patients - Canada
Soggetto genere / forma Electronic books.
Soggetto non controllato Canadian health care system
cancer imagery
cancer narrative
cancer
coping with cancer
creativity and cancer
doctor/patient relationship
illness memoir
kidney cancer
meaning of illness
poetry and cancer
thinking through cancer
wait times for surgery
ISBN 1-77112-190-4
1-77112-189-0
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910155160203321
Sherman Kenneth <1950-, >  
Waterloo, Ontario : , : Wilfrid Laurier University Press, , [2016]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui